Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
For locally advanced esophagogastric junction and gastric cancer (cT3-4aNxM0 or cT2N2-3M0),
neoadjuvant chemotherapy can downstage T and N stage,treated distant micrometastases early
before local therapy has begun, and finally improve the long-term survival. Combination of
perioperative PD-1 antibody and chemotherapy for locally advanced esophagogastric junction
and gastric cancer could be a novel therapy to increase response rate and reduce recurrence
rate. JS001 in this study is a Chinese anti-PD-1 monoclonal antibody for injection which has
been approved for melanoma. This study is a multi-center, open-label, randomized phase II
clinical trial to evaluate safety and efficacy of JS001 in combination with perioperative
chemotherapy in locally advanced esophagogastric junction and gastric cancer. Differences in
gut microbiome and tumor immune microenvironment were detected to screen people who were more
sensitive to immunotherapy.